Electromed, Inc. Form 10-Q Summary
Reporting period: Fiscal quarter and nine months ended March 31, 2024, filed May 7, 2024. The source metadata identifies “2023 Q3,” but the filing is for Electromed’s third quarter of fiscal 2024. Electromed develops, manufactures, and markets SmartVest high-frequency chest wall oscillation airway-clearance systems for homecare and hospital markets.
Financial Results and Position
| Metric | Q3 FY2024 | Q3 FY2023 | Change |
|---|---|---|---|
| Net revenue | $13.871 million | $12.068 million | +14.9% |
| Gross profit | $10.382 million | $9.056 million | +14.6% |
| Gross margin | 74.8% | 75.0% | Down 0.2 points |
| Operating income | $1.841 million | $1.196 million | +53.9% |
| Net income | $1.493 million | $1.075 million | +38.9% |
| Diluted EPS | $0.17 | $0.12 | Increase |
| Metric | Nine Months FY2024 | Nine Months FY2023 | Change |
|---|---|---|---|
| Net revenue | $39.884 million | $34.455 million | +15.8% |
| Gross profit | $30.425 million | $26.069 million | +16.7% |
| Gross margin | 76.3% | 75.7% | Up 0.6 points |
| Operating income | $4.246 million | $2.514 million | +68.9% |
| Net income | $3.322 million | $2.133 million | +55.7% |
| Diluted EPS | $0.38 | $0.25 | Increase |
Margins: Q3 operating margin was approximately 13.3% versus 9.9% in the prior-year quarter; net margin was approximately 10.8% versus 8.9%. For the nine-month periods, operating margin was approximately 10.6% versus 7.3%, and net margin was approximately 8.3% versus 6.2%.
Revenue mix: Q3 homecare revenue increased 12.0% to $12.287 million, hospital revenue increased 78.0% to $783,000, homecare distributor revenue increased 4.6% to $524,000, and other revenue increased 77.6% to $277,000. Homecare represented approximately 88.6% of Q3 revenue.
Balance sheet and liquidity: Cash and cash equivalents were $11.712 million at March 31, 2024, versus $7.372 million at June 30, 2023. Working capital was $34.996 million. Total assets were $48.901 million and total shareholders’ equity was $42.544 million. The company had no outstanding borrowings under its $2.5 million revolving credit facility, and the full facility was available at quarter-end.
Cash flow: Nine-month operating cash flow was $4.578 million versus $316,000 in the prior-year period. Investing cash use was $349,000, including $265,000 for property and equipment and $84,000 for intangible assets. Financing cash provided was $111,000 from stock-option exercises. Ending cash increased $4.340 million from June 30, 2023.
Debt and covenants: The revolving facility expires in December 2025 if not renewed, bears interest at the prime rate less 1.0%, and is secured by substantially all tangible and intangible assets. It includes a minimum tangible net worth covenant of $10.125 million and restrictions on additional indebtedness and dividends.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven primarily by additional direct sales representatives and reimbursement-process efficiencies in homecare, as well as higher hospital capital and disposable demand.
- SG&A increased 8.8% in Q3 and 12.0% for the nine months, primarily due to higher payroll, compensation, sales personnel, travel, marketing, and share-based compensation costs.
- Nine-month share-based compensation expense increased to $1.250 million from $506,000, including $217,000 related to performance-based restricted stock units.
- Research and development expense declined 22.3% for the nine months because major development costs for the SmartVest Clearway platform largely occurred in the prior year.
- Q3 gross margin declined slightly because of costs associated with winding down previous generator models. Nine-month gross margin improved due primarily to lower shipping expenses and the absence of prior-year expedited inventory costs.
- Net interest income increased to $293,000 for the nine months from $37,000 because of higher cash balances and savings rates.
- The company adopted the expected-credit-loss accounting standard effective July 1, 2023; adoption had no material financial-statement impact.
Outlook, Risks, Contingencies, and Unusual Items
- Management believes cash, operating cash flow, working capital, and available credit will be sufficient for anticipated needs for at least the next twelve months and for fiscal 2024 requirements.
- A Change Healthcare cybersecurity incident delayed non-Medicare claims submissions by approximately three weeks. Nearly 75% of delayed claims had been resolved by quarter-end; the cash-flow impact was less than $1.0 million for the quarter, and management expected resolution by June 30, 2024.
- The company paid $825,000 into a settlement fund related to a previously disclosed cybersecurity breach; the payment was covered by insurance.
- Key risks include reimbursement changes or denials by Medicare, Medicaid, and private insurers; healthcare regulation; supply shortages and inflation; competition; sales-force expansion; product and technology issues; cybersecurity incidents; international regulation; regulatory approvals; intellectual-property protection; and renewal or availability of credit.
- The company maintains a warranty reserve of $1.525 million at March 31, 2024. U.S. patient products generally carry lifetime warranties, while hospital and non-U.S. individual sales generally carry three-year warranties.
- Management reported no material pending legal proceedings, no defaults under senior securities, and effective disclosure controls as of the evaluation date.
- No quarterly share repurchases occurred. Approximately $275,000 remained available under the repurchase authorization at March 31, 2024.
Investor Verification Points
- Confirm the filing period: March 31, 2024, representing Q3 of fiscal 2024 rather than calendar 2023 Q3.
- Assess whether homecare growth and hospital-market expansion are sustainable after adjusting for distributor and international purchase timing.
- Monitor reimbursement collections, contract-asset estimates, accounts receivable, and any lingering effects from the Change Healthcare disruption.
- Evaluate the effect of higher compensation, marketing, travel, and share-based compensation expenses on future operating leverage.
- Review warranty, inventory-obsolescence, variable-consideration, and credit-loss estimates for potential future adjustments.
- Verify continued compliance with the credit facility’s tangible-net-worth and other covenants, despite there being no balance outstanding at quarter-end.
- Review future reimbursement, regulatory, cybersecurity, supply-chain, competitive, and product-clearance developments.